SlideShare a Scribd company logo
1 of 66
1
SCREENING METHODS OF
ANTI HYPERTENSIVE AGENTS
Dr.Swaroopa, 1st year pg,
Department of pharmacology
2
CONTENTS
 INTRODUCTION
 REGULATION OF HYPERTENSION
 SCREENING MODELS
 CONCLUSION
 REFERENCES
3
INTRODUCTION
 Hypertension is a complex multifactorial disease and one of the
leading causes of mortality and morbidity (92 million disability-
adjusted life years worldwide were attributable to high blood
pressure)
 Hypertension doubles the risk of cardiovascular diseases, including
coronary heart disease (CHD), congestive heart failure (CHF),
ischemic and haemorrhagic stroke, renal failure, and peripheral
arterial disease.
 The prevalence of hypertension increases with age, among
individuals age ≥60, it is 65.4%.
Harrison’s principles of Internal medicine, 20th Edition, Hypertensive Vascular Disease,
SK Gupta, Drug screening methods, Antihypertensive agents.
4
Contd……
 As the etiology of essential hypertension is not specific and is
multifactorial, the use of experimental animal models may provide
valuable information regarding many aspects of the disease,
 Which include etiology, pathophysiology, complications and treatment.
HYPERTENSION
 Hypertension is defined as a sustained increase in blood
pressure of 140/90 mmHg or higher, a criterion that
characterizes a group of patients whose risk of hypertension-
related cardiovascular disease is high enough to merit
medical attention.
 Isolated systolic hypertension : defined as systolic blood
pressure greater than 140mmHg with diastolic blood
pressure less than 90 mmHg, is largely confined to people
older than 60 years.
6
Classification
Blood
Systolic BP
pressure(mmHg)
Diastolic BP
Normal <120 <80
Prehypertension 120-139 80-89
Hypertension, stage1 140-159 90-99
Hypertension, stage 2 >160 >100
Hypertensive crisis >180 >110
Goodman and Gilman, 13th edition, The Pharmacological Basis of Therapeutics, Section III,
Treatment of Hypertension, pg 507 – 526
AMERICAN HEART ASSOCIATION CRITERIA FOR HYPERTENSION IN
ADULTS
7
Bertram G Katzung, Antihypertensive agents. Basics & Clinical Pharmacology, McGraw Hill,
New Delhi, 14th edition;2018, pg-173 – 193
8
Screening methods of Antihypertensive agents:
 The animal models of hypertension share many features which are common to
human Hypertension.
 Many of these models have been developed by utilizing the etiological factors
that are presumed to be responsible for human hypertension like excessive salt
intake, Hyperactivity of Renin-Angiotensin-Aldosterone-System(RAAS) and
genetic factors.
9
ANIMALS USED
 Earlier, most studies on experimental hypertension were
carried out on Dogs.
 Currently, Rat is the preferred species.
 Spontaneous Hypertensive Rat(SHR), the genetic strain of
hypertensive rat, is the animal of choice.
10
SCREENING MODELS
IN VIVO MODELS:-
 Acute renal hypertension in Rats
 Chronic Renal Hypertension in Rats
 Chronic Renal Hypertension in Dogs
 Neurogenic Hypertension in Dogs
 DOCA-salt Induced Hypertension in Rats
 Fructose Induced Hypertension in Rats
 Genetic Hypertension in Rats
 Hypertension Induced by Chronic NO-synthase Inhibition
 Portal Hypertension in Rats
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
11
 Pulmonary Hypertension Induced by Monocrotaline
 Endothelin Receptor Antagonism in Porcine Isolated Hearts
IN VITRO MODELS:
12
Methods of inducing renovascular hypertension
Goldblatt Method :- Goldblatt et.al (1934)
Three variants of hypertension are produced by
this method.
1. Two kidney one clip method(2K1C)
2. One kidney one clip method(1K1C)
3. Two kidney two clip method(2K2C)
13
Acute Renal Hypertension in Rats/2K1C
Principle used :
Ischemia of the kidneys causes elevation of blood pressure by
activation of renin-angiotensin system.
Clamping of renal artery for 4h
Accumulated renin released into
circulation after releasing the vessel
Protease renin catalyses the first & rate
limiting step in the formation of
angiotensin2
Acute hypertension Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce
experimental Hypertension, pg no -239 .
14
Procedure: Male Sprague-Dawley rats weighing 300 g are
anesthetized by intraperitoneal injection of 100
mg/kg hexobarbital sodium.
A PVC-coated clip is placed onto the left hilum
of the kidney and fixed to the back muscles.
The renal artery is occluded for 3.5–4 h.
The animals are anesthetized by intraperitoneal
injection of 30–40 mg/kg pentobarbital sodium.
The trachea is cannulated to facilitate
spontaneous respiration.
Voge l& vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg no -239
15
The cannula in the carotid artery is connected to a pressure
transducer to measure systolic and diastolic blood pressures.
For administration of the test compound, a jugular vein is cannulated.
After obtaining stable reduced blood pressure values, ganglionic blockade is
performed with pentolinium(10mg/kg i.v.) and the renal arterial clip is removed.
This leads to a rise in blood pressure as a consequence of elevated
plasma renin level. Within 15 min a stable hypertension is
achieved (control = 100%).
Voge l& vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg no -239
16
The test substance is then administered by intravenous
injection at doses of 10 and 100 µg/kg.
Blood pressure is monitored continuously until an
increased level to the starting level is obtained.
Ten–twelve
animals are
used per
compound.
Vogel & vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg no -239
17
 Increase in blood pressure is determined after reopening of the
renal artery.
 Reduction in blood pressure is determined after administration
of the test drug.
 Percent inhibition of hypertensive blood pressure values under
drug treatment are calculated as compared to pretreatment
hypertension values.
 Duration of the effect is determined [min].
 Statistical significance is assessed by the paired t-test.
EVALUATION :
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
18
MODIFICATIONS OF THE METHOD:
cardiogenic hypertensive chemo reflex
Sharp and transient increase in systemic arterial blood
pressure associated with reflex bradycardia can be elicited by
injection of 5-hydroxytryptamine, cyanide, nicotine or
lobeline into the coronary artery blood stream of dogs
(Berthold et al. 1989)
5-HT proved to be the
most powerful agent
for its initiation
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
19
Chronic Renal Hypertension in Rats/1K1C method:
This is One of the most effective modifications in rats.
Procedure:
Male Sprague-Dawley rats weighing 200–250 g are
anaesthetized with 50 mg/kg i.p. pentobarbital.
The fur on the back is shaved and the skin disinfected. In the left
lumbar area a flank incision is made parallel to the long axis of the rat.
The renal pedicel is exposed with the kidney retracted to the abdomen.
The renal artery is dissected clean and a U-shaped silver clip is slipped
around it near the aorta.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
20
The right kidney is removed through a flank incision after tying off
the renal pedicle. The skin incisions are closed by wound clips.
4–5 weeks after clipping blood pressure is measured and rats with
values higher than 150 mm Hg are selected for the experiments.
Blood pressure readings are taken on each of 3 days prior to drug
treatment.
Drugs are administered orally in volumes of 10 ml/kg.
Compounds are administered for 3 days and predrug and
postdrug(2h) blood pressure readings are taken.
The rats are
divided into 4
animals per dose
and each animal
is used as his
own control
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
21
 Activity is determined by comparing treatment blood pressure
values with the control blood pressure value (Day 1, predrug
blood pressure).
 Comparisons are made using the paired t-test for evaluation of
statistical significance.
EVALUATION
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
MODIFICATIONS OF THE METHOD
Duan et al. (1996) induced renal hypertension in male Hartley
guinea pigs by a two-step procedure consisting of ligation of
the left caudal renal artery and right nephrectomy.
Arterial blood pressure and heart rate were monitored in
conscious animals.
ACE-inhibitors reduced blood pressure in sham-operated and in
renal hypertensive guinea pigs,
whereas renin inhibitors were effective only in renal hypertensive
animals
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
23
Chronic Renal Hypertension in Dogs
• first described by Goldblatt et al. (1934) in dogs.
• The method has been modified as the “wrapping” technique (Abram and Sobin 1947).
PROCEDURE
Dogs weighing 8–12 kg are anesthetized with i.v. injection of 15 mg/kg
thiopental. Anesthesia is maintained with a halothane-oxygen mixture.
Under aseptic conditions, a midline abdominal incision is made
One kidney is exposed and wrapped in cellophane and then replaced.
The contralateral kidney is exposed.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
24
The artery, vein and ureter are ligated and the kidney is
removed. The abdomen is closed by sutures and clips
On the day of surgery and for 3 days following, the dogs are given
antibiotics. Body temperature is measured twice daily for 4 days
following surgery.
Six weeks following surgery, blood pressure is measured using a tail-cuff
method. For recording, the tail cuff is attached to a polygraph.
Only animals with a systolic blood pressure higher than 150 mm Hg are
considered to be hypertensive and can participate in studies evaluating
potential antihypertensive compounds.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
25
Blood pressure is recorded either by the indirect tail-cuff
method or by direct measurement via an implanted arterial
cannula.
On day 1 readings are made every 2 h, just before, and 2
and 4 h after oral treatment with the potential
antihypertensive compound. Drug administration is
repeated for 5 days.
On days 3 and 5 blood pressure readings are taken before
and 2 and 4 h after treatment.
At least 3
dogs are
used per
dose and
compound.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
26
EVALUATION
 The starting value is the average of the 2 readings
before application of the drug.
 Each of the following readings is subtracted from
this value and recorded as fall of blood pressure at
the various recording times.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
27
MODIFICATIONS OF THE METHOD
1. Technique according to Grollman (1944).
• The kidney is exposed through a lumbar incision,
• The renal capsule is removed by gentle traction,
• A figure-8ligature is applied being tight enough to deform the
kidney but not tight enough to cut the tissue.
2. Technique according to Abrams and Sobin 1947
• Renal hypertension may be induced in the rat by encapsulating
both kidneys with latex rubber capsules
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
28
• Moulds are formed from plastic using a rat kidney as a model.
• The capsules are prepared by dipping the moulds in liquid latex
allowing them to dry in the air.
• Three applications of latex are applied before the capsules are
toughened by placing them under warm running tap water.
• The kidney is exposed by lumbar incision, the renal capsule gently
removed and the capsule applied.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
29
Vasodilator and depressor reflexes, originating in the
baroreceptor areas of the carotid sinus and aortic arch, play
an important part in the regulation of blood pressure.
Neurogenic Hypertension in Dogs
Stimulation of the afferent buffer fibres exerts an inhibitory
influence on the vasomotor center, and their sectioning leads to a
persistent rise in blood pressure.
Acute neurogenic hypertension can be induced in dogs
Principle :
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
30
PROCEDURE Adult dogs of either sex weighing 10–15 kg are anesthetized using 15
mg/kg sodium thiopental, 200 mg/kg sodium barbital and 60 mg/kg
sodium pentobarbital i.v.
A femoral vein and artery are cannulated using polyethylene
tubing to administer compounds i.v and record arterial
pressure and heart rate, respectively
Left ventricular pressure is recorded via the left common carotid
artery (post-deafferentiation) using a Millar micro tip pressure
transducer.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
31
Pmax is recorded by speeding up the chart paper.
Cardiac output is determined by introducing a Swan-Ganz catheter
into the right heart and pulmonary artery via a jugular vein.
5 ml of cold 5% dextrose is injected into the right atrium and
an Edwards Cardiac output computer is used to calculate the
cardiac output from the temperature change in the
pulmonary artery.
All recordings are made with a polygraph.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
32
Both of the carotid arteries are cleared up to the bifurcation of the
internal and external carotid arteries.
The carotid sinus nerves are isolated, ligated and sectioned and a
bilateral vagotomy is performed to produce neurogenic hypertension
(mean arterial pressure more than 150 mm Hg).
The dog is allowed to equilibrate for approximately 30
min and a bolus of the test compound is administered by
intravenous injection.
Heart rate, arterial pressure, left ventricular pressure,
Pmax and are monitored for 90 min.
minimum of
3 dogs are
used for
each
compound.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
33
EVALUATION
Changes of the cardiovascular parameters are expressed as
percentage of the values before administration of the drug.
MODIFICATIONS OF THE METHOD
Neurogenic hypertension through baroreceptor denervation has
also been described in rabbits (Angell James 1984) and in rats
(Krieger 1984).
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
34
CRITICAL ASSESSMENT OF THE METHOD
• The neurogenic hypertension is useful for acute
experiments.
• It is less useful for chronic experiments since the
elevated blood pressure caused by buffer nerve section is
more labile than that caused by renal ischemia.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
35
DOCA-salt Induced Hypertension in Rats
(desoxycorticosteroneacetate)
Mineralocorticoid-induced hypertension
sodium retaining properties of the steroid
increases in plasma and extracellular volume
The hypertensive effect
is increased by salt
loading and unilateral
nephrectomy in rats.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
36
Male Sprague Dawley rats weighing 250–300 g
are anesthetized with ether.
PROCEDURE
Through a flank incision the left kidney is removed.
The rats are injected twice weekly with 20 mg/kg s.c.
desoxycorticosteroneacetate in olive oil for 4 weeks.
Drinking water is replaced with a 1% NaCl solution. B
Blood pressure starts to rise after one week and reaches
systolic values between 160 and 180 mm Hg after 4
weeks
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
37
MODIFICATIONS OF THE METHOD
 The regimen to induce DOCA-salt hypertension modified by
many authors (Stanton 1971).
 DOCA-salt hypertension can also be achieved without
nephrectomy (Bockman et al. 1992).
 Using kininogen-deficient Brown Norway Katholiek (BN-Ka) rats,
Majima et al. (1991, 1993) showed suppression of rat
desoxycorticosterone-salt hypertension by the kallikrein-kinin
system.
 Li et al. (1996) examined small-artery structure on a wire myograph
and quantified endothelin-1 messenger RNA by Northern blot analysis
in DOCA-salt hypertensive rats after administration of an ACE-
inhibitor, a calcium channel antagonist and a nitric oxide synthase
inhibitor.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
38
Fructose Induced Hypertension in Rats
The increased intake of either sucrose or glucose was shown to enhance the
development of either spontaneous hypertension or salt hypertension in rats
(Hall and Hall 1966).
Hwang et al. (1987) first reported that hypertension could be induced in
normal rats by feeding a high-fructose diet. F
Fructose feeding was also found to cause insulin resistance,
hyperinsulinemia, and hypertriglyceridemia in normal rats (Zavaroni et al.
1980; Tobey et al. 1982).
Tobey et al. 1982). Dai and McNeill (1995) studied the concentration- and
duration-dependence of fructose induced hypertension in rats.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
39
PROCEDURE
Groups of 8 male Wistar rats weighing 210–250 g are used.
The are housed two per cage on a 12-h light 12- h dark cycle and are
allowed free access to standard laboratory diet (Purina rat chow) and
drinking fluid
Drinking fluid consists either of tap water or 10%- fructose solution
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
40
Blood samples are collected before and every second
week during treatment for determination of plasma
glucose, insulin, and triglycerides.
Body weight, food intake and fluid intake of each rat are
measured every week during treatment.
Using the tail-cuff method, systolic blood pressure and pulse
rate is measured before and every week during treatment.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
41
EVALUATION
The duration of treatment 6 weeks.
Statistical analysis is performed using a one-way or two-
way analysis of variance, followed by the Newman-Keuls
test.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
42
MODIFICATIONS OF THE METHOD
• Reaven et al. (1988, 1989) found an attenuation of fructose-induced
hypertension by exercise training and an inhibition by somatostatin
treatment.
• Brands et al. (1991, 1992) found an increase of arterial
pressure during chronic hyperinsulinemia in conscious rats.
• Hall et al. (1995) reported the effects of 6 weeks of a high-fat
diet on cardiovascular, renal, and endocrine functions in
chronically instrumented conscious dogs. Body weight
increased by approximately 16.9 kg, whereas MAP, cardiac
output, and heart rate increased by 28%, 77%, and 68%,
respectively
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
43
Genetic Hypertension in Rats
Inherited hypertension in rats has been described by Smik and Hall
1958;
Phelan 1968 as genetically hypertensive (GH) rats (Simpson and
Phelan 1984).
Okamoto et al. (1963, 1966) reported the development
of a strain of spontaneously hypertensive rats from
mating one Wistar male rat with spontaneously
occurring high blood pressure with a female with
slightly elevated blood pressure.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
44
Hypertension in these rats is clearly hereditary and genetically
determined, thus comparable to primary hypertension in humans.
Cardiac hypertrophy (Sen et al. 1974) and cellular ionic transport
abnormalities have been observed (Yamori 1984).
By inbreeding over several generations a high incidence of
hypertension with blood pressure values of 200 mm Hg or more
was achieved.
These strains were called “Spontaneously hypertensive rats
(Akamoto-Aoki)” = SHR or “Wistar–Kyoto rats” =WKY
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
45
• Inbred strains being salt-hypertension-sensitive and salt-hypertension-
resistant (RD) have been developed by Dahl et al.
• Another hypertensive strain derived from Wistar rats was produced by
brother-sister mating in the group of Bianchi et al. (1974, 1986) at the
University of Milan called “Milan hypertensive strain” = MHS.
• These rats show a cell membrane defect resulting in abnormal kidney
function. Salvati et al. (1990) studied the diuretic effect of bumetanide
in isolated perfused kidneys of Milan hypertensive rats
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
46
• Several substrains of spontaneous hypertensive rats were separated
by the group of Okamoto et al. (1974) including the stroke-prone
strain SHR = SHRSP.
• These rats have an increased sympathetic tone and show a high
incidence of hemorrhagic lesions of the brain with motor
disturbances followed by death
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
47
• Bohlender et al. (1996) reconstructed the human renin-angiotensin
system in transgenic rats overexpressing the human angiotensin gene
TGR(hOGEN) 1623 by chronically injecting human recombinant renin
intravenously using Alzet pumps.
• Zolk et al. (1998) described the effects of quinapril, losartan and
hydralazine on cardiac hypertrophy and β-adrenergic neuroeffector
mechanisms in transgenic TGR(mREN2)27 rats.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
48
CRITICAL ASSESSMENT OF THE METHOD
On the basis of available data no preference can be given to a particular
strain
Transgenic rats with well defined genomes are gaining more importance.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
49
MODIFICATIONS OF THE METHOD
• Pijl et al. (1994) described streptozotocin-induced diabetes mellitus
in spontaneously hypertensive rats as a pathophysiological model for
the combined effects of hypertension and diabetes.
• Rosenthal et al. (1997) used rats of the CohenRosenthal diabetic
hypertensive strain to examine the effects of an ACE-inhibitor, an
ATII antagonist and a calcium antagonist on systolic pressure and
spontaneous blood glucose levels.
• Holycross et al. (1997) used hypertensive SHHF/ Mcc-facp rats to
study plasma renin activity during development of heart failure
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
50
• Linz et al. (1997) compared the outcome of lifelong treatment with
the ACE inhibitor Ramipril in young prehypertensive stroke-prone
spontaneously hypertensive rats and age-matched normotensive
Wistar–Kyoto rats.
• Lifelong ACE inhibition doubled the lifespan in hypertensive rats
matching that of normotensive
• Ohkubo et al. (1990) generated transgenic mice with elevated blood
pressure by introduction of the rat renin and angiotensinogen genes.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
51
Hypertension Induced by Chronic NO-Synthase Inhibition
Chronic blockade of NO synthesis in the rat produces systemic
hypertension and glomerular damage (Baylis et al. 1992). This
was recommended by Ribeiro et al. (1992) as a model of
hypertension.
The detrimental sequels of chronic NO synthase inhibition in rats can
be inhibited by treatment with ACE inhibitors.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
52
PROCEDURE Male Wistar rats at an age of 7–8 weeks weighing
210± 10 g were placed at random in metabolic
cages, divided in four to six groups of six to eight
rats each.
Group 1 (control) had free access to tap water
and food.
Groups 2–4 were treated with 0.02% L-NAME
water solution for 6 weeks in a daily dose of 25
mg/kg.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
53
Groups 3 and 4 received the angiotensin receptor antagonists
fonsartan (10 mg/kg) or lorsatan (30 mg/kg) for 6 weeks daily
per stomach tube.
Groups 5 and 6 received fonsartan and lorasatan alone.
At the end of the study, 24-h urine samples were collected and
retrobulbar blood samples were taken in short inhalation
anesthesia.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
54
For clearance evaluation rats were anesthetized with 50 mg/kg thiopentone i.p.
In order to determine glomerular filtration rate and renal plasma flow, clearances
of inulin and para-aminohippurate were performed.
EVALUATION
Results are presented as arithmetical means ± SEM.
A one-way ANOVA was calculated with SYSTAT for Windows (SYSTAT,
Evanston, Ill., USA) followed by multiple pairwise comparisons according to
Tukey.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
55
MODIFICATIONS OF THE METHOD
 Arnal et al. (1993) measured cardiac weight of rats in
hypertension induced by NO synthase blockade.
 Linz et al. (1999) reviewed the interactions between ACE, kinins
and NO.
 Sampaio et al. (2002) reported that hypertension plus diabetes
mimics the cardiomyopathy induced by NO inhibition in rats.
 Rossi et al. (2003) found that chronic inhibition of NO synthase
induces hypertension and cardiomyocyte mitochondrial and
myocardial remodeling in the absence of hypertrophy
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
56
Portal Hypertension in Rats
Portal hypertension is associated with hyperdynamic splanchnic
circulation and reduced vascular resistance (Vorobioff et al. 1983).
Tanoue et al. (1991) developed a method for inducing portal
hypertension and esophageal varices in rats – partial ligation of
the portal vein after devascularization of the circumference of
the left renal vein and complete ligation of the portal vein on
the fifth day thereafter.
Tsugawa et al. (2000) used this model to study the role of nitric
oxide and endothelin-1 in rat portal hypertension.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
57
Male Sprague-Dawley rats were anesthetized
with 50 mg/kg Nembutal intraperitoneally.
PROCEDURE
The portal vein was isolated and stenosis created by a single ligature of
3–0 silk placed around the portal vein and a 20-gauge blunt-tipped
needle after devascularization of the left renal vein.
This devascularization is indispensable in preventing the development
of excess collateral vessels, which inhibit the formation of esophageal
varices and the portal hypertensive state.
3–0 silk was also placed at the area of partial ligation (loose ligation),
and both ends were then drawn out through the abdominal wall.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
58
Five days after the operation, the ends of the silk that had been
placed in the flank were simultaneously pulled to induce
complete portal vein ligation.
Two weeks later, this portal hypertension model was completed.
Portal venous pressure, blood flow volume in the intra-
abdominal viscera, plasma NO and plasma endothelin-1 were
measure
EVALUATION
Results were expressed as mean ± standard deviation. The Student’s t-test
was used to determine significance between portal hypertension rats and
sham-operated controls.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
59
MODIFICATIONS OF THE METHOD
• Portal hypertension by portal vein ligation without devascularization of the left
renal vein was used by Lee et al. (1985), Braillon et al. (1986), Oren et al. (1995),
Fernandez et al. (1996), Moreno et al. (1996),
• Dieguez et al. (2002) used a surgical technique based on the development of a
triple stenosing ligation to worsen the complications inherent to the prehepatic
chronic portal hypertension.
• Jaffe et al. (1994) and Li et al. (1998) used injection of different sized
microspheres into the portal vein of male Wistar rats to induce portal
hypertension.
Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental
Hypertension, pg. no -239 -250
60
METHODS TO MEASURE BP IN RATS
Direct method:
• It is an invasive method .
• Femoral/carotid cannula is inserted into an anaesthetized animal.
• On day of screening, cannula is connected to a pressure transducer
then to the pre-amplifier.
• BP is recorded on the polygraph.
61
Indirect /Non invasive method:
Tail cuff method:
• It is a common and convenient method.
• Tail cuff is inflated and deflated
• Pulsations disappear when cuff is inflated.
• Pulsations start appearing when pressure
in the cuff equals systolic pressure while
deflating.
• The cuff is attached to a tail cuff
sphygmomanometer or pressure
transducer and BP is recorded on a chart.
62
Effects of antihypertensive agents
Antihypertensive drugs, according to their mode of action, will affect the blood
pressure in certain types of experimental hypertension, and not in all.
Vasodilators like Minoxidil, Hydralazine and Diazoxide are effective in Renal
hypertensive rats.
Calcium channel blockers, ACE Inhibitors and AT-1 antagonists decrease BP in
nephrectomised SHR.
Diuretics, are active in mineralocorticoid or salt induced hypertension.
Sympathomimetic Drugs decrease BP in both endocrine and neurogenic
hypertension.
63
64
CONCLUSION
The most important point from direct comparison of these animal
models is that, despite the well-known heterogeneity of
hypertension, the outcome of hypertension can be similar in some
respects.
Not all classes of antihypertensives are equally effective in all rat
models of hypertension.
These models of hypertension provide ample opportunity not only
to investigate the mechanisms involved in the pathogenesis of
hypertension, but also to learn about the critical balance between
stress and its overcoming which eventually determines prognosis.
65
REFERENCES
• Vogel & Vogel, 3rd edition, Drug discovery and evaluation ,chapter A2, methods to induce
experimental Hypertension, pg. no -239 -250.
• SK. Gupta, Drug screening methods, chapter16, Antihypertensive agents, pg.no 266-276.
• www.slideshare.net
66

More Related Content

What's hot

Screening of Drugs of Atherosclerosis
Screening of Drugs of AtherosclerosisScreening of Drugs of Atherosclerosis
Screening of Drugs of AtherosclerosisJaineel Dharod
 
Screening method of nootropics vikas malik
Screening method of nootropics vikas malikScreening method of nootropics vikas malik
Screening method of nootropics vikas malikVikasMalik68
 
Pharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agentsPharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agentsAbin Joy
 
Immunoassay of digoxin
Immunoassay of digoxinImmunoassay of digoxin
Immunoassay of digoxinAfreen Hashmi
 
Preclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic DrugsPreclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic DrugsShubham Kolge
 
Screening models on aphrodisiac agents
Screening models on aphrodisiac agentsScreening models on aphrodisiac agents
Screening models on aphrodisiac agentsJaineel Dharod
 
screening methods for anti-atherosclerotic agents
screening methods for anti-atherosclerotic agentsscreening methods for anti-atherosclerotic agents
screening methods for anti-atherosclerotic agentsPrajitha p
 
Drug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agentsDrug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agentsDr. Abhishek Vyas
 
Screening models for aphrodisiac agents and anti fertility agents
Screening models for aphrodisiac agents and anti fertility agentsScreening models for aphrodisiac agents and anti fertility agents
Screening models for aphrodisiac agents and anti fertility agentsCh. Bhargava krishna
 
Screening of antipyretic drugs
Screening of antipyretic drugsScreening of antipyretic drugs
Screening of antipyretic drugsdrarunsingh4
 
Screening of anti emetics drug
Screening of anti emetics drugScreening of anti emetics drug
Screening of anti emetics drugRajeshwar Yadav
 
Pharmacological screening of anti arrhythmic drugs 3
Pharmacological screening of anti arrhythmic drugs 3Pharmacological screening of anti arrhythmic drugs 3
Pharmacological screening of anti arrhythmic drugs 3pharmacologyseminars
 
screening methods for Antiepileptic activity
screening methods for Antiepileptic activityscreening methods for Antiepileptic activity
screening methods for Antiepileptic activitySravanthi Shetty
 
screening of antiulcer agents
screening  of antiulcer agentsscreening  of antiulcer agents
screening of antiulcer agentsUttara Joshi
 
Screening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugsScreening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugsHimikaRathi
 
Screening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseScreening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseAnupam dubey
 
Multiple sclerosis screening methods
Multiple sclerosis screening methodsMultiple sclerosis screening methods
Multiple sclerosis screening methodsmohamed abusalih
 

What's hot (20)

Screening of Drugs of Atherosclerosis
Screening of Drugs of AtherosclerosisScreening of Drugs of Atherosclerosis
Screening of Drugs of Atherosclerosis
 
Screening method of nootropics vikas malik
Screening method of nootropics vikas malikScreening method of nootropics vikas malik
Screening method of nootropics vikas malik
 
Pharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agentsPharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agents
 
Immunoassay of digoxin
Immunoassay of digoxinImmunoassay of digoxin
Immunoassay of digoxin
 
Preclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic DrugsPreclinical Screening of Antiasthmatic Drugs
Preclinical Screening of Antiasthmatic Drugs
 
Screening models on aphrodisiac agents
Screening models on aphrodisiac agentsScreening models on aphrodisiac agents
Screening models on aphrodisiac agents
 
screening methods for anti-atherosclerotic agents
screening methods for anti-atherosclerotic agentsscreening methods for anti-atherosclerotic agents
screening methods for anti-atherosclerotic agents
 
Drug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agentsDrug screening methods for antiarrhythmic agents
Drug screening methods for antiarrhythmic agents
 
Screening models for aphrodisiac agents and anti fertility agents
Screening models for aphrodisiac agents and anti fertility agentsScreening models for aphrodisiac agents and anti fertility agents
Screening models for aphrodisiac agents and anti fertility agents
 
Screening of antipyretic drugs
Screening of antipyretic drugsScreening of antipyretic drugs
Screening of antipyretic drugs
 
Screening of anti emetics drug
Screening of anti emetics drugScreening of anti emetics drug
Screening of anti emetics drug
 
Pharmacological screening of anti arrhythmic drugs 3
Pharmacological screening of anti arrhythmic drugs 3Pharmacological screening of anti arrhythmic drugs 3
Pharmacological screening of anti arrhythmic drugs 3
 
screening methods for Antiepileptic activity
screening methods for Antiepileptic activityscreening methods for Antiepileptic activity
screening methods for Antiepileptic activity
 
Screening models on behavioral and muscle coordination converted
Screening models on behavioral and muscle coordination convertedScreening models on behavioral and muscle coordination converted
Screening models on behavioral and muscle coordination converted
 
Screening of antiparkinsonian agents
Screening of antiparkinsonian agentsScreening of antiparkinsonian agents
Screening of antiparkinsonian agents
 
screening of antiulcer agents
screening  of antiulcer agentsscreening  of antiulcer agents
screening of antiulcer agents
 
Screening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugsScreening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugs
 
Screening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseScreening Methods of Parkinson's Disease
Screening Methods of Parkinson's Disease
 
Screening of anti hypertensives2003
Screening of anti hypertensives2003Screening of anti hypertensives2003
Screening of anti hypertensives2003
 
Multiple sclerosis screening methods
Multiple sclerosis screening methodsMultiple sclerosis screening methods
Multiple sclerosis screening methods
 

Similar to Screening methods of anti hypertensive agents

Screening methods for the evaluation of antihypertensive agents activity of a...
Screening methods for the evaluation of antihypertensive agents activity of a...Screening methods for the evaluation of antihypertensive agents activity of a...
Screening methods for the evaluation of antihypertensive agents activity of a...SuchiJain7
 
Animal Models for anti-hypertensive Drugs
Animal Models for anti-hypertensive DrugsAnimal Models for anti-hypertensive Drugs
Animal Models for anti-hypertensive DrugsMegh Vithalkar
 
screening of antihypertensive drugs.pptx
screening of antihypertensive drugs.pptxscreening of antihypertensive drugs.pptx
screening of antihypertensive drugs.pptxShivangiVaish5
 
Antihypertensives.pptx
Antihypertensives.pptxAntihypertensives.pptx
Antihypertensives.pptxsharanuGurikar
 
Preclinical Sreening of Antihypertensive agents.pptx
Preclinical Sreening of Antihypertensive agents.pptxPreclinical Sreening of Antihypertensive agents.pptx
Preclinical Sreening of Antihypertensive agents.pptxShraddhaRaut43
 
Evaluation of antihypertensive drugs
Evaluation of antihypertensive drugsEvaluation of antihypertensive drugs
Evaluation of antihypertensive drugsAshishkumar Baheti
 
Screening of antihypertensiveagent by raunak
Screening of antihypertensiveagent by raunakScreening of antihypertensiveagent by raunak
Screening of antihypertensiveagent by raunakRaunakkumar Chaurasiya
 
Antihypertensive and antidiarrhoeal drugs preclinical screening
Antihypertensive and antidiarrhoeal drugs preclinical screeningAntihypertensive and antidiarrhoeal drugs preclinical screening
Antihypertensive and antidiarrhoeal drugs preclinical screeningDHINESHKUMAR V
 
Preclinical Screening of Antihypertensive Agents | In-Vitro & In-Vivo Models
Preclinical Screening of Antihypertensive Agents | In-Vitro & In-Vivo ModelsPreclinical Screening of Antihypertensive Agents | In-Vitro & In-Vivo Models
Preclinical Screening of Antihypertensive Agents | In-Vitro & In-Vivo ModelsChetan Prakash
 
[9] Animal Models of Hypertension.pptx
[9] Animal Models of Hypertension.pptx[9] Animal Models of Hypertension.pptx
[9] Animal Models of Hypertension.pptxArriyanAbrham
 
Antihypertensive Screening Models
Antihypertensive Screening ModelsAntihypertensive Screening Models
Antihypertensive Screening ModelsVishnuPrabhakar26
 
0c9605215046f7a34f000000
0c9605215046f7a34f0000000c9605215046f7a34f000000
0c9605215046f7a34f000000terencehilado
 
efedrina y dopa en isofluorano.pdf
efedrina y dopa en isofluorano.pdfefedrina y dopa en isofluorano.pdf
efedrina y dopa en isofluorano.pdfleroleroero1
 
Screening methods for antihypertensive drugs.pptx
Screening methods for antihypertensive drugs.pptxScreening methods for antihypertensive drugs.pptx
Screening methods for antihypertensive drugs.pptxMuralidharRaoAkkalad
 
Screening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsScreening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsDr. Advaitha MV
 
Potential role of uric acid in correlation with epidemics of hypertension and...
Potential role of uric acid in correlation with epidemics of hypertension and...Potential role of uric acid in correlation with epidemics of hypertension and...
Potential role of uric acid in correlation with epidemics of hypertension and...Apollo Hospitals
 
conns primary hyperaldosteronism last .pptx
conns primary hyperaldosteronism last .pptxconns primary hyperaldosteronism last .pptx
conns primary hyperaldosteronism last .pptxHamadAlablani2
 

Similar to Screening methods of anti hypertensive agents (20)

Screening methods for the evaluation of antihypertensive agents activity of a...
Screening methods for the evaluation of antihypertensive agents activity of a...Screening methods for the evaluation of antihypertensive agents activity of a...
Screening methods for the evaluation of antihypertensive agents activity of a...
 
Animal Models for anti-hypertensive Drugs
Animal Models for anti-hypertensive DrugsAnimal Models for anti-hypertensive Drugs
Animal Models for anti-hypertensive Drugs
 
screening of antihypertensive drugs.pptx
screening of antihypertensive drugs.pptxscreening of antihypertensive drugs.pptx
screening of antihypertensive drugs.pptx
 
Antihypertensives.pptx
Antihypertensives.pptxAntihypertensives.pptx
Antihypertensives.pptx
 
Preclinical Sreening of Antihypertensive agents.pptx
Preclinical Sreening of Antihypertensive agents.pptxPreclinical Sreening of Antihypertensive agents.pptx
Preclinical Sreening of Antihypertensive agents.pptx
 
Evaluation of antihypertensive drugs
Evaluation of antihypertensive drugsEvaluation of antihypertensive drugs
Evaluation of antihypertensive drugs
 
International Journal of Clinical & Experimental Hypertension
International Journal of Clinical & Experimental HypertensionInternational Journal of Clinical & Experimental Hypertension
International Journal of Clinical & Experimental Hypertension
 
Screening of antihypertensiveagent by raunak
Screening of antihypertensiveagent by raunakScreening of antihypertensiveagent by raunak
Screening of antihypertensiveagent by raunak
 
Antihypertensive and antidiarrhoeal drugs preclinical screening
Antihypertensive and antidiarrhoeal drugs preclinical screeningAntihypertensive and antidiarrhoeal drugs preclinical screening
Antihypertensive and antidiarrhoeal drugs preclinical screening
 
Preclinical Screening of Antihypertensive Agents | In-Vitro & In-Vivo Models
Preclinical Screening of Antihypertensive Agents | In-Vitro & In-Vivo ModelsPreclinical Screening of Antihypertensive Agents | In-Vitro & In-Vivo Models
Preclinical Screening of Antihypertensive Agents | In-Vitro & In-Vivo Models
 
[9] Animal Models of Hypertension.pptx
[9] Animal Models of Hypertension.pptx[9] Animal Models of Hypertension.pptx
[9] Animal Models of Hypertension.pptx
 
Antihypertensive Screening Models
Antihypertensive Screening ModelsAntihypertensive Screening Models
Antihypertensive Screening Models
 
0c9605215046f7a34f000000
0c9605215046f7a34f0000000c9605215046f7a34f000000
0c9605215046f7a34f000000
 
efedrina y dopa en isofluorano.pdf
efedrina y dopa en isofluorano.pdfefedrina y dopa en isofluorano.pdf
efedrina y dopa en isofluorano.pdf
 
Screening methods for antihypertensive drugs.pptx
Screening methods for antihypertensive drugs.pptxScreening methods for antihypertensive drugs.pptx
Screening methods for antihypertensive drugs.pptx
 
Screening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsScreening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive Agents
 
Potential role of uric acid in correlation with epidemics of hypertension and...
Potential role of uric acid in correlation with epidemics of hypertension and...Potential role of uric acid in correlation with epidemics of hypertension and...
Potential role of uric acid in correlation with epidemics of hypertension and...
 
Anti hypertensive
Anti hypertensive Anti hypertensive
Anti hypertensive
 
ABG5 Series
ABG5  SeriesABG5  Series
ABG5 Series
 
conns primary hyperaldosteronism last .pptx
conns primary hyperaldosteronism last .pptxconns primary hyperaldosteronism last .pptx
conns primary hyperaldosteronism last .pptx
 

More from SwaroopaNallabariki

Drugs having Pleiotropic effects, Nutraceuticals and role of antioxidants ant...
Drugs having Pleiotropic effects, Nutraceuticals and role of antioxidants ant...Drugs having Pleiotropic effects, Nutraceuticals and role of antioxidants ant...
Drugs having Pleiotropic effects, Nutraceuticals and role of antioxidants ant...SwaroopaNallabariki
 
Gn rh analogues and therapeutics by swaroopa
Gn rh analogues and therapeutics by swaroopaGn rh analogues and therapeutics by swaroopa
Gn rh analogues and therapeutics by swaroopaSwaroopaNallabariki
 
Drugs affecting haematopoiesis and recent advances by swaroopa
Drugs affecting haematopoiesis and recent advances by swaroopaDrugs affecting haematopoiesis and recent advances by swaroopa
Drugs affecting haematopoiesis and recent advances by swaroopaSwaroopaNallabariki
 
Acute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animalsAcute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animalsSwaroopaNallabariki
 

More from SwaroopaNallabariki (10)

Opioid agonists & antagonists
Opioid agonists & antagonistsOpioid agonists & antagonists
Opioid agonists & antagonists
 
Drugs having Pleiotropic effects, Nutraceuticals and role of antioxidants ant...
Drugs having Pleiotropic effects, Nutraceuticals and role of antioxidants ant...Drugs having Pleiotropic effects, Nutraceuticals and role of antioxidants ant...
Drugs having Pleiotropic effects, Nutraceuticals and role of antioxidants ant...
 
Gn rh analogues and therapeutics by swaroopa
Gn rh analogues and therapeutics by swaroopaGn rh analogues and therapeutics by swaroopa
Gn rh analogues and therapeutics by swaroopa
 
Drugs affecting haematopoiesis and recent advances by swaroopa
Drugs affecting haematopoiesis and recent advances by swaroopaDrugs affecting haematopoiesis and recent advances by swaroopa
Drugs affecting haematopoiesis and recent advances by swaroopa
 
beta lactam antibiotics
beta lactam antibioticsbeta lactam antibiotics
beta lactam antibiotics
 
Adrenergic agonists by swaroopa
Adrenergic agonists by swaroopaAdrenergic agonists by swaroopa
Adrenergic agonists by swaroopa
 
Animal toxicity studies
Animal toxicity studiesAnimal toxicity studies
Animal toxicity studies
 
Acute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animalsAcute and chronic toxicity studies in animals
Acute and chronic toxicity studies in animals
 
Phase 3
Phase 3Phase 3
Phase 3
 
Phase 0 clinical trials
Phase 0 clinical trialsPhase 0 clinical trials
Phase 0 clinical trials
 

Recently uploaded

ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptxENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptxAnaBeatriceAblay2
 
_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting Data_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting DataJhengPantaleon
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 
internship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerinternship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerunnathinaik
 
Science lesson Moon for 4th quarter lesson
Science lesson Moon for 4th quarter lessonScience lesson Moon for 4th quarter lesson
Science lesson Moon for 4th quarter lessonJericReyAuditor
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
Blooming Together_ Growing a Community Garden Worksheet.docx
Blooming Together_ Growing a Community Garden Worksheet.docxBlooming Together_ Growing a Community Garden Worksheet.docx
Blooming Together_ Growing a Community Garden Worksheet.docxUnboundStockton
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfMahmoud M. Sallam
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionSafetyChain Software
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxsocialsciencegdgrohi
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17Celine George
 
Biting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfBiting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfadityarao40181
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
 

Recently uploaded (20)

ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptxENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
ENGLISH5 QUARTER4 MODULE1 WEEK1-3 How Visual and Multimedia Elements.pptx
 
_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting Data_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting Data
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 
internship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerinternship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developer
 
Science lesson Moon for 4th quarter lesson
Science lesson Moon for 4th quarter lessonScience lesson Moon for 4th quarter lesson
Science lesson Moon for 4th quarter lesson
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
Blooming Together_ Growing a Community Garden Worksheet.docx
Blooming Together_ Growing a Community Garden Worksheet.docxBlooming Together_ Growing a Community Garden Worksheet.docx
Blooming Together_ Growing a Community Garden Worksheet.docx
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdf
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory Inspection
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17How to Configure Email Server in Odoo 17
How to Configure Email Server in Odoo 17
 
Biting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfBiting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdf
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
 

Screening methods of anti hypertensive agents

  • 1. 1 SCREENING METHODS OF ANTI HYPERTENSIVE AGENTS Dr.Swaroopa, 1st year pg, Department of pharmacology
  • 2. 2 CONTENTS  INTRODUCTION  REGULATION OF HYPERTENSION  SCREENING MODELS  CONCLUSION  REFERENCES
  • 3. 3 INTRODUCTION  Hypertension is a complex multifactorial disease and one of the leading causes of mortality and morbidity (92 million disability- adjusted life years worldwide were attributable to high blood pressure)  Hypertension doubles the risk of cardiovascular diseases, including coronary heart disease (CHD), congestive heart failure (CHF), ischemic and haemorrhagic stroke, renal failure, and peripheral arterial disease.  The prevalence of hypertension increases with age, among individuals age ≥60, it is 65.4%. Harrison’s principles of Internal medicine, 20th Edition, Hypertensive Vascular Disease, SK Gupta, Drug screening methods, Antihypertensive agents.
  • 4. 4 Contd……  As the etiology of essential hypertension is not specific and is multifactorial, the use of experimental animal models may provide valuable information regarding many aspects of the disease,  Which include etiology, pathophysiology, complications and treatment.
  • 5. HYPERTENSION  Hypertension is defined as a sustained increase in blood pressure of 140/90 mmHg or higher, a criterion that characterizes a group of patients whose risk of hypertension- related cardiovascular disease is high enough to merit medical attention.  Isolated systolic hypertension : defined as systolic blood pressure greater than 140mmHg with diastolic blood pressure less than 90 mmHg, is largely confined to people older than 60 years.
  • 6. 6 Classification Blood Systolic BP pressure(mmHg) Diastolic BP Normal <120 <80 Prehypertension 120-139 80-89 Hypertension, stage1 140-159 90-99 Hypertension, stage 2 >160 >100 Hypertensive crisis >180 >110 Goodman and Gilman, 13th edition, The Pharmacological Basis of Therapeutics, Section III, Treatment of Hypertension, pg 507 – 526 AMERICAN HEART ASSOCIATION CRITERIA FOR HYPERTENSION IN ADULTS
  • 7. 7 Bertram G Katzung, Antihypertensive agents. Basics & Clinical Pharmacology, McGraw Hill, New Delhi, 14th edition;2018, pg-173 – 193
  • 8. 8 Screening methods of Antihypertensive agents:  The animal models of hypertension share many features which are common to human Hypertension.  Many of these models have been developed by utilizing the etiological factors that are presumed to be responsible for human hypertension like excessive salt intake, Hyperactivity of Renin-Angiotensin-Aldosterone-System(RAAS) and genetic factors.
  • 9. 9 ANIMALS USED  Earlier, most studies on experimental hypertension were carried out on Dogs.  Currently, Rat is the preferred species.  Spontaneous Hypertensive Rat(SHR), the genetic strain of hypertensive rat, is the animal of choice.
  • 10. 10 SCREENING MODELS IN VIVO MODELS:-  Acute renal hypertension in Rats  Chronic Renal Hypertension in Rats  Chronic Renal Hypertension in Dogs  Neurogenic Hypertension in Dogs  DOCA-salt Induced Hypertension in Rats  Fructose Induced Hypertension in Rats  Genetic Hypertension in Rats  Hypertension Induced by Chronic NO-synthase Inhibition  Portal Hypertension in Rats Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 11. 11  Pulmonary Hypertension Induced by Monocrotaline  Endothelin Receptor Antagonism in Porcine Isolated Hearts IN VITRO MODELS:
  • 12. 12 Methods of inducing renovascular hypertension Goldblatt Method :- Goldblatt et.al (1934) Three variants of hypertension are produced by this method. 1. Two kidney one clip method(2K1C) 2. One kidney one clip method(1K1C) 3. Two kidney two clip method(2K2C)
  • 13. 13 Acute Renal Hypertension in Rats/2K1C Principle used : Ischemia of the kidneys causes elevation of blood pressure by activation of renin-angiotensin system. Clamping of renal artery for 4h Accumulated renin released into circulation after releasing the vessel Protease renin catalyses the first & rate limiting step in the formation of angiotensin2 Acute hypertension Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg no -239 .
  • 14. 14 Procedure: Male Sprague-Dawley rats weighing 300 g are anesthetized by intraperitoneal injection of 100 mg/kg hexobarbital sodium. A PVC-coated clip is placed onto the left hilum of the kidney and fixed to the back muscles. The renal artery is occluded for 3.5–4 h. The animals are anesthetized by intraperitoneal injection of 30–40 mg/kg pentobarbital sodium. The trachea is cannulated to facilitate spontaneous respiration. Voge l& vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg no -239
  • 15. 15 The cannula in the carotid artery is connected to a pressure transducer to measure systolic and diastolic blood pressures. For administration of the test compound, a jugular vein is cannulated. After obtaining stable reduced blood pressure values, ganglionic blockade is performed with pentolinium(10mg/kg i.v.) and the renal arterial clip is removed. This leads to a rise in blood pressure as a consequence of elevated plasma renin level. Within 15 min a stable hypertension is achieved (control = 100%). Voge l& vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg no -239
  • 16. 16 The test substance is then administered by intravenous injection at doses of 10 and 100 µg/kg. Blood pressure is monitored continuously until an increased level to the starting level is obtained. Ten–twelve animals are used per compound. Vogel & vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg no -239
  • 17. 17  Increase in blood pressure is determined after reopening of the renal artery.  Reduction in blood pressure is determined after administration of the test drug.  Percent inhibition of hypertensive blood pressure values under drug treatment are calculated as compared to pretreatment hypertension values.  Duration of the effect is determined [min].  Statistical significance is assessed by the paired t-test. EVALUATION : Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 18. 18 MODIFICATIONS OF THE METHOD: cardiogenic hypertensive chemo reflex Sharp and transient increase in systemic arterial blood pressure associated with reflex bradycardia can be elicited by injection of 5-hydroxytryptamine, cyanide, nicotine or lobeline into the coronary artery blood stream of dogs (Berthold et al. 1989) 5-HT proved to be the most powerful agent for its initiation Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 19. 19 Chronic Renal Hypertension in Rats/1K1C method: This is One of the most effective modifications in rats. Procedure: Male Sprague-Dawley rats weighing 200–250 g are anaesthetized with 50 mg/kg i.p. pentobarbital. The fur on the back is shaved and the skin disinfected. In the left lumbar area a flank incision is made parallel to the long axis of the rat. The renal pedicel is exposed with the kidney retracted to the abdomen. The renal artery is dissected clean and a U-shaped silver clip is slipped around it near the aorta. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 20. 20 The right kidney is removed through a flank incision after tying off the renal pedicle. The skin incisions are closed by wound clips. 4–5 weeks after clipping blood pressure is measured and rats with values higher than 150 mm Hg are selected for the experiments. Blood pressure readings are taken on each of 3 days prior to drug treatment. Drugs are administered orally in volumes of 10 ml/kg. Compounds are administered for 3 days and predrug and postdrug(2h) blood pressure readings are taken. The rats are divided into 4 animals per dose and each animal is used as his own control Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 21. 21  Activity is determined by comparing treatment blood pressure values with the control blood pressure value (Day 1, predrug blood pressure).  Comparisons are made using the paired t-test for evaluation of statistical significance. EVALUATION Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 22. MODIFICATIONS OF THE METHOD Duan et al. (1996) induced renal hypertension in male Hartley guinea pigs by a two-step procedure consisting of ligation of the left caudal renal artery and right nephrectomy. Arterial blood pressure and heart rate were monitored in conscious animals. ACE-inhibitors reduced blood pressure in sham-operated and in renal hypertensive guinea pigs, whereas renin inhibitors were effective only in renal hypertensive animals Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 23. 23 Chronic Renal Hypertension in Dogs • first described by Goldblatt et al. (1934) in dogs. • The method has been modified as the “wrapping” technique (Abram and Sobin 1947). PROCEDURE Dogs weighing 8–12 kg are anesthetized with i.v. injection of 15 mg/kg thiopental. Anesthesia is maintained with a halothane-oxygen mixture. Under aseptic conditions, a midline abdominal incision is made One kidney is exposed and wrapped in cellophane and then replaced. The contralateral kidney is exposed. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 24. 24 The artery, vein and ureter are ligated and the kidney is removed. The abdomen is closed by sutures and clips On the day of surgery and for 3 days following, the dogs are given antibiotics. Body temperature is measured twice daily for 4 days following surgery. Six weeks following surgery, blood pressure is measured using a tail-cuff method. For recording, the tail cuff is attached to a polygraph. Only animals with a systolic blood pressure higher than 150 mm Hg are considered to be hypertensive and can participate in studies evaluating potential antihypertensive compounds. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 25. 25 Blood pressure is recorded either by the indirect tail-cuff method or by direct measurement via an implanted arterial cannula. On day 1 readings are made every 2 h, just before, and 2 and 4 h after oral treatment with the potential antihypertensive compound. Drug administration is repeated for 5 days. On days 3 and 5 blood pressure readings are taken before and 2 and 4 h after treatment. At least 3 dogs are used per dose and compound. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 26. 26 EVALUATION  The starting value is the average of the 2 readings before application of the drug.  Each of the following readings is subtracted from this value and recorded as fall of blood pressure at the various recording times. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 27. 27 MODIFICATIONS OF THE METHOD 1. Technique according to Grollman (1944). • The kidney is exposed through a lumbar incision, • The renal capsule is removed by gentle traction, • A figure-8ligature is applied being tight enough to deform the kidney but not tight enough to cut the tissue. 2. Technique according to Abrams and Sobin 1947 • Renal hypertension may be induced in the rat by encapsulating both kidneys with latex rubber capsules Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 28. 28 • Moulds are formed from plastic using a rat kidney as a model. • The capsules are prepared by dipping the moulds in liquid latex allowing them to dry in the air. • Three applications of latex are applied before the capsules are toughened by placing them under warm running tap water. • The kidney is exposed by lumbar incision, the renal capsule gently removed and the capsule applied. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 29. 29 Vasodilator and depressor reflexes, originating in the baroreceptor areas of the carotid sinus and aortic arch, play an important part in the regulation of blood pressure. Neurogenic Hypertension in Dogs Stimulation of the afferent buffer fibres exerts an inhibitory influence on the vasomotor center, and their sectioning leads to a persistent rise in blood pressure. Acute neurogenic hypertension can be induced in dogs Principle : Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 30. 30 PROCEDURE Adult dogs of either sex weighing 10–15 kg are anesthetized using 15 mg/kg sodium thiopental, 200 mg/kg sodium barbital and 60 mg/kg sodium pentobarbital i.v. A femoral vein and artery are cannulated using polyethylene tubing to administer compounds i.v and record arterial pressure and heart rate, respectively Left ventricular pressure is recorded via the left common carotid artery (post-deafferentiation) using a Millar micro tip pressure transducer. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 31. 31 Pmax is recorded by speeding up the chart paper. Cardiac output is determined by introducing a Swan-Ganz catheter into the right heart and pulmonary artery via a jugular vein. 5 ml of cold 5% dextrose is injected into the right atrium and an Edwards Cardiac output computer is used to calculate the cardiac output from the temperature change in the pulmonary artery. All recordings are made with a polygraph. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 32. 32 Both of the carotid arteries are cleared up to the bifurcation of the internal and external carotid arteries. The carotid sinus nerves are isolated, ligated and sectioned and a bilateral vagotomy is performed to produce neurogenic hypertension (mean arterial pressure more than 150 mm Hg). The dog is allowed to equilibrate for approximately 30 min and a bolus of the test compound is administered by intravenous injection. Heart rate, arterial pressure, left ventricular pressure, Pmax and are monitored for 90 min. minimum of 3 dogs are used for each compound. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 33. 33 EVALUATION Changes of the cardiovascular parameters are expressed as percentage of the values before administration of the drug. MODIFICATIONS OF THE METHOD Neurogenic hypertension through baroreceptor denervation has also been described in rabbits (Angell James 1984) and in rats (Krieger 1984). Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 34. 34 CRITICAL ASSESSMENT OF THE METHOD • The neurogenic hypertension is useful for acute experiments. • It is less useful for chronic experiments since the elevated blood pressure caused by buffer nerve section is more labile than that caused by renal ischemia. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 35. 35 DOCA-salt Induced Hypertension in Rats (desoxycorticosteroneacetate) Mineralocorticoid-induced hypertension sodium retaining properties of the steroid increases in plasma and extracellular volume The hypertensive effect is increased by salt loading and unilateral nephrectomy in rats. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 36. 36 Male Sprague Dawley rats weighing 250–300 g are anesthetized with ether. PROCEDURE Through a flank incision the left kidney is removed. The rats are injected twice weekly with 20 mg/kg s.c. desoxycorticosteroneacetate in olive oil for 4 weeks. Drinking water is replaced with a 1% NaCl solution. B Blood pressure starts to rise after one week and reaches systolic values between 160 and 180 mm Hg after 4 weeks Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 37. 37 MODIFICATIONS OF THE METHOD  The regimen to induce DOCA-salt hypertension modified by many authors (Stanton 1971).  DOCA-salt hypertension can also be achieved without nephrectomy (Bockman et al. 1992).  Using kininogen-deficient Brown Norway Katholiek (BN-Ka) rats, Majima et al. (1991, 1993) showed suppression of rat desoxycorticosterone-salt hypertension by the kallikrein-kinin system.  Li et al. (1996) examined small-artery structure on a wire myograph and quantified endothelin-1 messenger RNA by Northern blot analysis in DOCA-salt hypertensive rats after administration of an ACE- inhibitor, a calcium channel antagonist and a nitric oxide synthase inhibitor. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 38. 38 Fructose Induced Hypertension in Rats The increased intake of either sucrose or glucose was shown to enhance the development of either spontaneous hypertension or salt hypertension in rats (Hall and Hall 1966). Hwang et al. (1987) first reported that hypertension could be induced in normal rats by feeding a high-fructose diet. F Fructose feeding was also found to cause insulin resistance, hyperinsulinemia, and hypertriglyceridemia in normal rats (Zavaroni et al. 1980; Tobey et al. 1982). Tobey et al. 1982). Dai and McNeill (1995) studied the concentration- and duration-dependence of fructose induced hypertension in rats. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 39. 39 PROCEDURE Groups of 8 male Wistar rats weighing 210–250 g are used. The are housed two per cage on a 12-h light 12- h dark cycle and are allowed free access to standard laboratory diet (Purina rat chow) and drinking fluid Drinking fluid consists either of tap water or 10%- fructose solution Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 40. 40 Blood samples are collected before and every second week during treatment for determination of plasma glucose, insulin, and triglycerides. Body weight, food intake and fluid intake of each rat are measured every week during treatment. Using the tail-cuff method, systolic blood pressure and pulse rate is measured before and every week during treatment. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 41. 41 EVALUATION The duration of treatment 6 weeks. Statistical analysis is performed using a one-way or two- way analysis of variance, followed by the Newman-Keuls test. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 42. 42 MODIFICATIONS OF THE METHOD • Reaven et al. (1988, 1989) found an attenuation of fructose-induced hypertension by exercise training and an inhibition by somatostatin treatment. • Brands et al. (1991, 1992) found an increase of arterial pressure during chronic hyperinsulinemia in conscious rats. • Hall et al. (1995) reported the effects of 6 weeks of a high-fat diet on cardiovascular, renal, and endocrine functions in chronically instrumented conscious dogs. Body weight increased by approximately 16.9 kg, whereas MAP, cardiac output, and heart rate increased by 28%, 77%, and 68%, respectively Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 43. 43 Genetic Hypertension in Rats Inherited hypertension in rats has been described by Smik and Hall 1958; Phelan 1968 as genetically hypertensive (GH) rats (Simpson and Phelan 1984). Okamoto et al. (1963, 1966) reported the development of a strain of spontaneously hypertensive rats from mating one Wistar male rat with spontaneously occurring high blood pressure with a female with slightly elevated blood pressure. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 44. 44 Hypertension in these rats is clearly hereditary and genetically determined, thus comparable to primary hypertension in humans. Cardiac hypertrophy (Sen et al. 1974) and cellular ionic transport abnormalities have been observed (Yamori 1984). By inbreeding over several generations a high incidence of hypertension with blood pressure values of 200 mm Hg or more was achieved. These strains were called “Spontaneously hypertensive rats (Akamoto-Aoki)” = SHR or “Wistar–Kyoto rats” =WKY Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 45. 45 • Inbred strains being salt-hypertension-sensitive and salt-hypertension- resistant (RD) have been developed by Dahl et al. • Another hypertensive strain derived from Wistar rats was produced by brother-sister mating in the group of Bianchi et al. (1974, 1986) at the University of Milan called “Milan hypertensive strain” = MHS. • These rats show a cell membrane defect resulting in abnormal kidney function. Salvati et al. (1990) studied the diuretic effect of bumetanide in isolated perfused kidneys of Milan hypertensive rats Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 46. 46 • Several substrains of spontaneous hypertensive rats were separated by the group of Okamoto et al. (1974) including the stroke-prone strain SHR = SHRSP. • These rats have an increased sympathetic tone and show a high incidence of hemorrhagic lesions of the brain with motor disturbances followed by death Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 47. 47 • Bohlender et al. (1996) reconstructed the human renin-angiotensin system in transgenic rats overexpressing the human angiotensin gene TGR(hOGEN) 1623 by chronically injecting human recombinant renin intravenously using Alzet pumps. • Zolk et al. (1998) described the effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β-adrenergic neuroeffector mechanisms in transgenic TGR(mREN2)27 rats. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 48. 48 CRITICAL ASSESSMENT OF THE METHOD On the basis of available data no preference can be given to a particular strain Transgenic rats with well defined genomes are gaining more importance. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 49. 49 MODIFICATIONS OF THE METHOD • Pijl et al. (1994) described streptozotocin-induced diabetes mellitus in spontaneously hypertensive rats as a pathophysiological model for the combined effects of hypertension and diabetes. • Rosenthal et al. (1997) used rats of the CohenRosenthal diabetic hypertensive strain to examine the effects of an ACE-inhibitor, an ATII antagonist and a calcium antagonist on systolic pressure and spontaneous blood glucose levels. • Holycross et al. (1997) used hypertensive SHHF/ Mcc-facp rats to study plasma renin activity during development of heart failure Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 50. 50 • Linz et al. (1997) compared the outcome of lifelong treatment with the ACE inhibitor Ramipril in young prehypertensive stroke-prone spontaneously hypertensive rats and age-matched normotensive Wistar–Kyoto rats. • Lifelong ACE inhibition doubled the lifespan in hypertensive rats matching that of normotensive • Ohkubo et al. (1990) generated transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 51. 51 Hypertension Induced by Chronic NO-Synthase Inhibition Chronic blockade of NO synthesis in the rat produces systemic hypertension and glomerular damage (Baylis et al. 1992). This was recommended by Ribeiro et al. (1992) as a model of hypertension. The detrimental sequels of chronic NO synthase inhibition in rats can be inhibited by treatment with ACE inhibitors. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 52. 52 PROCEDURE Male Wistar rats at an age of 7–8 weeks weighing 210± 10 g were placed at random in metabolic cages, divided in four to six groups of six to eight rats each. Group 1 (control) had free access to tap water and food. Groups 2–4 were treated with 0.02% L-NAME water solution for 6 weeks in a daily dose of 25 mg/kg. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 53. 53 Groups 3 and 4 received the angiotensin receptor antagonists fonsartan (10 mg/kg) or lorsatan (30 mg/kg) for 6 weeks daily per stomach tube. Groups 5 and 6 received fonsartan and lorasatan alone. At the end of the study, 24-h urine samples were collected and retrobulbar blood samples were taken in short inhalation anesthesia. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 54. 54 For clearance evaluation rats were anesthetized with 50 mg/kg thiopentone i.p. In order to determine glomerular filtration rate and renal plasma flow, clearances of inulin and para-aminohippurate were performed. EVALUATION Results are presented as arithmetical means ± SEM. A one-way ANOVA was calculated with SYSTAT for Windows (SYSTAT, Evanston, Ill., USA) followed by multiple pairwise comparisons according to Tukey. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 55. 55 MODIFICATIONS OF THE METHOD  Arnal et al. (1993) measured cardiac weight of rats in hypertension induced by NO synthase blockade.  Linz et al. (1999) reviewed the interactions between ACE, kinins and NO.  Sampaio et al. (2002) reported that hypertension plus diabetes mimics the cardiomyopathy induced by NO inhibition in rats.  Rossi et al. (2003) found that chronic inhibition of NO synthase induces hypertension and cardiomyocyte mitochondrial and myocardial remodeling in the absence of hypertrophy Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 56. 56 Portal Hypertension in Rats Portal hypertension is associated with hyperdynamic splanchnic circulation and reduced vascular resistance (Vorobioff et al. 1983). Tanoue et al. (1991) developed a method for inducing portal hypertension and esophageal varices in rats – partial ligation of the portal vein after devascularization of the circumference of the left renal vein and complete ligation of the portal vein on the fifth day thereafter. Tsugawa et al. (2000) used this model to study the role of nitric oxide and endothelin-1 in rat portal hypertension. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 57. 57 Male Sprague-Dawley rats were anesthetized with 50 mg/kg Nembutal intraperitoneally. PROCEDURE The portal vein was isolated and stenosis created by a single ligature of 3–0 silk placed around the portal vein and a 20-gauge blunt-tipped needle after devascularization of the left renal vein. This devascularization is indispensable in preventing the development of excess collateral vessels, which inhibit the formation of esophageal varices and the portal hypertensive state. 3–0 silk was also placed at the area of partial ligation (loose ligation), and both ends were then drawn out through the abdominal wall. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 58. 58 Five days after the operation, the ends of the silk that had been placed in the flank were simultaneously pulled to induce complete portal vein ligation. Two weeks later, this portal hypertension model was completed. Portal venous pressure, blood flow volume in the intra- abdominal viscera, plasma NO and plasma endothelin-1 were measure EVALUATION Results were expressed as mean ± standard deviation. The Student’s t-test was used to determine significance between portal hypertension rats and sham-operated controls. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 59. 59 MODIFICATIONS OF THE METHOD • Portal hypertension by portal vein ligation without devascularization of the left renal vein was used by Lee et al. (1985), Braillon et al. (1986), Oren et al. (1995), Fernandez et al. (1996), Moreno et al. (1996), • Dieguez et al. (2002) used a surgical technique based on the development of a triple stenosing ligation to worsen the complications inherent to the prehepatic chronic portal hypertension. • Jaffe et al. (1994) and Li et al. (1998) used injection of different sized microspheres into the portal vein of male Wistar rats to induce portal hypertension. Vogel & Vogel, drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250
  • 60. 60 METHODS TO MEASURE BP IN RATS Direct method: • It is an invasive method . • Femoral/carotid cannula is inserted into an anaesthetized animal. • On day of screening, cannula is connected to a pressure transducer then to the pre-amplifier. • BP is recorded on the polygraph.
  • 61. 61 Indirect /Non invasive method: Tail cuff method: • It is a common and convenient method. • Tail cuff is inflated and deflated • Pulsations disappear when cuff is inflated. • Pulsations start appearing when pressure in the cuff equals systolic pressure while deflating. • The cuff is attached to a tail cuff sphygmomanometer or pressure transducer and BP is recorded on a chart.
  • 62. 62 Effects of antihypertensive agents Antihypertensive drugs, according to their mode of action, will affect the blood pressure in certain types of experimental hypertension, and not in all. Vasodilators like Minoxidil, Hydralazine and Diazoxide are effective in Renal hypertensive rats. Calcium channel blockers, ACE Inhibitors and AT-1 antagonists decrease BP in nephrectomised SHR. Diuretics, are active in mineralocorticoid or salt induced hypertension. Sympathomimetic Drugs decrease BP in both endocrine and neurogenic hypertension.
  • 63. 63
  • 64. 64 CONCLUSION The most important point from direct comparison of these animal models is that, despite the well-known heterogeneity of hypertension, the outcome of hypertension can be similar in some respects. Not all classes of antihypertensives are equally effective in all rat models of hypertension. These models of hypertension provide ample opportunity not only to investigate the mechanisms involved in the pathogenesis of hypertension, but also to learn about the critical balance between stress and its overcoming which eventually determines prognosis.
  • 65. 65 REFERENCES • Vogel & Vogel, 3rd edition, Drug discovery and evaluation ,chapter A2, methods to induce experimental Hypertension, pg. no -239 -250. • SK. Gupta, Drug screening methods, chapter16, Antihypertensive agents, pg.no 266-276. • www.slideshare.net
  • 66. 66